Skip to main content
Home Home

Wrap Treatment with Integrated Care Biograph® by Amwell for Life Sciences

When individuals can access treatment and follow the treatment plan, it is good for them, it is good for public health, and it is good for healthcare organizations.  

Sponsors can lead the way by pairing drugs with personalized support, digital engagement and ongoing guidance through the treatment journey.

 

One solution. Multiple treatment journeys. Enable better outcomes.  

Connect With Us

Why Leading Life Sciences Companies Are Investing in Connected Care 

Evolving regulatory policy is toward connected care.  

Undertreatment is a significant public health challenge. Rates of non-adherence remain high, with nearly half of patients not taking medications as prescribed.1 Individuals are, functionally, unsupervised self-managers most of the time due to gaps in access, bad data, and lack of follow-up.  

To close gaps, the FDA issued a final rule for Nonprescription Drug Products with an Additional Condition for Nonprescription Use (ACNU) intended to increase safe access to treatment through delivery models that connect care. At the same time, CMS policy and payment models are moving toward outcome-based, technology-enabled, continuously-supported chronic care—with emphasis on treatment adherence.

The result: a growing opportunity to pair therapies with relevant care programs and to improve access, engagement, and outcomes. 

  • Patients manage most of their care independently2
  • Access to providers remains limited in many communities3
  • Digital health adoption continues to grow4
  • New regulatory pathways support innovative treatment models5
  • Digital therapeutics reimbursement opportunities are expanding6,7

Why Biograph® by Amwell 

Enable Better Treatment Experiences and Outcomes.

Biograph® by Amwell helps life sciences organizations design, launch, and scale connected treatment programs. 

Our solution combines life sciences expertise with trusted digital care technology to help manufacturers: 

  • Improve engagement and adherence outcomes 
  • Expand treatment access 
  • Deliver personal and protocol-aligned treatment journeys 
  • Capture meaningful real-world insights and evidence 
  • Navigate evolving regulatory requirements 
  • Accelerate program launch timelines 
  • Create differentiating value 

More access and better treatment adherence is good for people and good for the population. From prescription therapies to self-directed treatments and digital therapeutics, we help bring treatment and support together in a single experience. 

Where It Creates Value

One Solution. Multiple Treatment Journeys.

  • Improve the Prescription Treatment Journey

    Support patients with personalized education, guidance, reminders, and care experiences designed to help improve treatment initiation, treatment adherence, and long-term engagement.

  • Unlock Nonprescription Access with Additional Conditions for Use (ACNU)

    Help consumers determine whether a treatment is right for them through guided digital experiences that support self-selection and appropriate use. 

  • Enhance Treatment Experiences with Integrated Care Programs

    Extend the value of therapies with integrated care designed to support monitoring, engagement, behavior change, and ongoing treatment success.

What You Stand to Gain

Benefits That Extend Beyond the Product

  • Accelerate Time to Market

    Launch connected care programs quickly with configurable technology and demonstrated implementation expertise.

  • Differentiate Your Products

    Deliver treatment experiences designed to create value beyond the therapy itself.

  • Increase Patient Engagement

    Help patients navigate treatment with fewer barriers and more personalized support.

  • Simplify Execution

    Operationalize program requirements with workflows designed for regulated healthcare environments.

  • Generate Actionable Insights and RWE

    Capture real-world engagement and outcomes data to inform future strategy and innovation. 

  • Scale Across Products and Portfolios

    Deploy once and adapt across therapies, brands, and patient populations.

How It Works

From Strategy to Scaled Execution

  • Opportunity & Program Design

    Identify where connected care can best meet patient needs and program objectives.

  • Personalized Assessment & Eligibility

    Guide patients and consumers through tailored screening and onboarding experiences. 

  • Smart Treatment Guidance

    Apply evidence-based, label-aligned protocols to deliver the right guidance, support, and next steps at the right moment in the journey.  

  • Connected Patient Experiences

    Create seamless digital experiences that help individuals learn, engage, and take action. (For ACNU, this includes secure completion confirmation that enables purchase in-store or online.) 

  • Integrated Data & Insights

    Bring together relevant patient, treatment, and program information to support better experiences and decision-making. 

  • QA, Reporting & Performance Measurement

    Track engagement, outcomes, and program performance with confidence. Maintain documentation, decision logs, attestations, and regulatory records.  

  • Outcomes & Real-World Evidence

    Capture engagement, eligibility, and outcomes data to strengthen safety monitoring and generate actionable insights. 

Expertise to Design. Technology to Deliver. Partnership to Scale. A Strategic Partner for the Future of Treatment

Success in today's healthcare environment requires more than an active ingredient. 

Biograph® by Amwell brings together deep life sciences expertise, connected care capabilities, and scalable technology to help organizations create treatment experiences designed to improve outcomes and strengthen competitive advantage. 

Hand holding a pill and a prescription pill bottle
Background gradient
Doctor with headset icon

A Better Treatment Experience: Drug + Integrated Care

Regulation is moving toward more connected care. Patients need and expect more support. The convergence creates an opportunity for integrated care in the treatment journey. Biograph® by Amwell helps life sciences companies deliver treatment experiences designed to increase access, empower patients, address regulatory requirements, and improve public health.
Connect With Us
  1. Pruitt SD, et al. “The silent epidemic of non-adherence – insights from the 2024 a congress.” BMC Proceedings. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12096470/ 
  2. Agency for Healthcare Research and Quality. “Patient Self-Management Support Programs: An Evaluation.” AHRQ. https://www.ahrq.gov/research/findings/final-reports/ptmgmt/summary.html 
  3. Health Resources and Services Administration. “Health Workforce Shortage Areas.” HRSA. https://data.hrsa.gov/topics/health-workforce/shortage-areas/dashboard 
  4. Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology. “Trends in Individuals’ Use of Health IT: 2012–2024.” HealthIT.gov. https://healthit.gov/data/quickstats/trends-individuals-use-health-it-2012-2024/ 
  5. U.S. Food and Drug Administration. “Nonprescription Drug Product with an Additional Condition for Nonprescription Use.” FDA. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/nonprescription-drug-product-additional-condition-nonprescription-use 
  6. Centers for Medicare & Medicaid Services. “Calendar Year (CY) 2025 Medicare Physician Fee Schedule Final Rule.” CMS. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2025-medicare-physician-fee-schedule-final-rule 
  7. Centers for Medicare & Medicaid Services. “Medicare Physician Fee Schedule Final Rule Summary: CY 2026.” CMS. https://www.cms.gov/files/document/mm14315-medicare-physician-fee-schedule-final-rule-summary-cy-2026.pdf